An oncology company with a ‘hub and spoke’ structure wished to commission an expert third-party due diligence on one of its spin-out companies in support of its next investment round. The target company was developing small molecule DNA damage response inhibitors against various protein targets and oncology indications.
Our expert team reviewed the target robustness, proof of concept data and commercial potential of two DDR inhibitor programs.
In addition, we reflected on the successes and failures of the PARPi space as whole and how this relates to the potential of other DDR inhibitors in the field.
Alacrita due diligence consultants have been a trusted DD source for close to fifteen years, conducting assignments for large pharma, biotech, universities and investors. Every due diligence we perform is underpinned by our ability to incorporate individuals into each project who have the exact matching expertise required for a complete, thorough and accurate assessment.